Cancer-associated thrombosis: enhanced awareness and pathophysiologic complexity.

Area of Science:

• Oncology
• Hematology
• Molecular Biology

Background:

• Thrombosis, encompassing both venous and arterial clots, is a significant contributor to illness and death in cancer patients.
• The intricate relationship between blood coagulation pathways and tumor biology has been increasingly elucidated, revealing novel molecular players.
• Cancer-associated thrombophilia presents unique challenges due to patient variability, tumor characteristics, and diverse anticancer therapies.

Purpose of the Study:

• To review key findings in the field of cancer and thrombosis, bridging fundamental tumor biology with clinical applications.
• To highlight advancements in understanding and managing cancer-related thrombotic events.
• To increase awareness among physicians and patients regarding cancer-associated thrombosis.

Main Methods:

• Comprehensive literature review of studies on cancer-associated thrombophilia.
• Analysis of the molecular basis linking coagulation pathways and tumor biology.
• Examination of clinical studies and guidelines for venous thromboembolism prophylaxis and treatment in cancer patients.
• Discussion of recent clinical trials involving novel anticoagulants for cancer patients.

Main Results:

• Established link between cancer and increased risk of thrombosis (venous and arterial).
• Identification of molecular mechanisms underlying cancer-associated thrombophilia.
• Development of clinical guidelines for venous thromboembolism management in oncology settings.
• Emergence of new anticoagulant therapies showing promise in clinical trials.

Conclusions:

• Cancer-associated thrombosis remains a critical clinical challenge requiring ongoing research and tailored management strategies.
• Continued exploration of the interplay between tumor biology and hemostasis is essential for therapeutic advancements.
• Enhanced awareness and multidisciplinary approaches are vital for optimizing patient outcomes.